#USA #New York #Securities Fraud #Rosen Law Firm #Geron Corporation

A Significant Opportunity for Geron Corporation Investors

In a recent alert from the Rosen Law Firm, investors in Geron Corporation (NASDAQ: GERN) are reminded of a critical moment to engage in legal actions related to securities fraud. The class period highlighted stretches from February 28, 2024, to February 25, 2025, and there is an approaching deadline for lead plaintiffs to emerge by May 12, 2025.

The Context of the Lawsuit

Rosen Law Firm has established itself as a staunch advocate for investor rights internationally and has issued reminders for those who purchased Geron securities during the specified time frame. The firm highlights that potential participants may seek compensation through a contingency fee arrangement, meaning that no upfront payment is necessary. This arrangement can be particularly advantageous, as it allows investors to engage in litigation without the burden of initial legal costs.

Call to Action for Investors

For investors wanting to participate in the class action, they are encouraged to visit Rosen's legal website or reach out directly to Phillip Kim, Esq. via phone or email for further information. Indeed, a class action lawsuit has already been initiated, but those looking to serve as lead plaintiffs must act quickly, ensuring their motions are submitted before the approaching deadline.

The Rosen Law Firm's Track Record

Rosen Law Firm is lauded for its seasoned expertise in securities class actions, with a history of achieving remarkable settlements, including major victories against Chinese companies and ranking first in securities class action settlements in 2017. The firm consistently ranks among the top firms in terms of the number of settlements secured each year and has recovered substantial amounts for its clients, exceeding hundreds of millions of dollars in total settlements.

Details from the Lawsuit

The lawsuit articulates allegations surrounding Geron's actions and statements, which purportedly misled investors about the prospects of the drug RYTELO. Key points from the claims include:
1. Defendants failed to address significant awareness issues among healthcare providers, which could impede the drug's market potential.
2. The launch of RYTELO was unlikely to generate the revenue levels that Geron publicly projected.
3. Overall, the company's statements significantly overstated their business outlook and financial health, resulting in investor damages once the truth emerged.

As the lawsuit unfolds, it is crucial for Geron investors to stay informed about the case's developments. Joining the class action will not only ensure that their voices are heard but also position them for any potential recovery that may arise from these proceedings.

Next Steps for Interested Investors

In order to take part in this class action, investors can select their legal counsel but are also reminded they don't have to be lead plaintiffs to benefit from any future settlements. Those interested should not delay in assessing their options as the deadline approaches swiftly. To stay updated, investors can follow Rosen Law Firm on social platforms, including LinkedIn, Twitter, and Facebook.

In summary, this is an essential moment for Geron Corporation investors. With the potential for significant financial recovery on the table and a competent law firm advocating for shareholders, this class action represents a vital opportunity for those affected by the alleged fraud.